Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
IPO Year: 2014
Exchange: NASDAQ
Website: ocugen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/17/2026 | $12.00 | Buy | Canaccord Genuity |
| 3/11/2026 | $10.00 | Outperform | Oppenheimer |
| 10/15/2024 | $4.00 | Buy | Maxim Group |
| 3/1/2023 | $3.50 | Neutral → Buy | Chardan Capital Markets |
| 8/23/2022 | $5.00 | Buy | Mizuho |
| 6/15/2022 | $8.00 | Buy | ROTH Capital |
| 6/2/2022 | $4.50 | Overweight | Cantor Fitzgerald |
| 2/28/2022 | $10.00 → $8.00 | Buy | HC Wainwright & Co. |
| 7/26/2021 | Outperform | Noble Capital Markets |
8-K - Ocugen, Inc. (0001372299) (Filer)
S-8 - Ocugen, Inc. (0001372299) (Filer)
10-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
SCHEDULE 13G - Ocugen, Inc. (0001372299) (Subject)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
424B5 - Ocugen, Inc. (0001372299) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
Fastest customizable press release news feed in the world
Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission.OCU410 positive preliminary Phase 2 data announced in January. Full Phase 2 data expected in March 2026. First regional licensing agreement for OCU400 in 2025 initiates strategic partnership strategy
Next-generation cellular therapies and regenerative medicine drive exponential expansionNEW YORK, March 3, 2026 /CNW/ -- Market News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for ways to stay healthier, more energetic, and more youthful. What was once considered a niche cosmetic category has evolved into a major healthcare and biotech opportunity. Industry forecasts project the broader anti-aging market could surpass $420 billion by 2030, growing at an estimated 8–9% compound annual growth rate (CAGR). This growth is being fueled by rising healthcare awareness, advances in biotechnology, and increased de
Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RPPositive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrates sustained clinically meaningful, approximately 2-line LLVA gain, reinforcing durable gene-agnostic benefit MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene ther
MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for net proceeds of $20.85 million, after deducting commissions and other estimated offering expenses payable by Ocugen. The financing was led by RTW Investments, with additional participation from new and existing investors. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for gross proceeds of $22.5 million, before deducting commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about January 22, 2026, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by Ocugen. The financing is being led by RTW Investments, with additional par
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to date MALVERN, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive preliminary 12-month data (~50% of patients evaluated to date) from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The global prevalence of dA
MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease, in the peer-reviewed journal Nature Eye—published by the Royal College of Ophthalmologists. The publication, A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights, was authored by Arshad M. Kh
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
3/A - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
3 - Ocugen, Inc. (0001372299) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Canaccord Genuity initiated coverage of Ocugen with a rating of Buy and set a new price target of $12.00
Oppenheimer initiated coverage of Ocugen with a rating of Outperform and set a new price target of $10.00
Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00
Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50
Mizuho initiated coverage of Ocugen with a rating of Buy and set a new price target of $5.00
ROTH Capital resumed coverage of Ocugen with a rating of Buy and set a new price target of $8.00
Cantor Fitzgerald initiated coverage of Ocugen with a rating of Overweight and set a new price target of $4.50
HC Wainwright & Co. reiterated coverage of Ocugen with a rating of Buy and set a new price target of $8.00 from $10.00 previously
Noble Capital Markets initiated coverage of Ocugen with a rating of Outperform
ROTH Capital downgraded Ocugen from Buy to Neutral and set a new price target of $6.00 from $10.00 previously
Live finance-specific insights
MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec
MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School
MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events section of
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial and on track for 2026 BLA filingOrthoCellix reverse merger intended to unlock the value of NeoCart/regenerative cell therapies and enable the Company to focus capital on modifier gene therapy platformSigned binding term sheet for exclusive Korean rights to OCU400 with upfront fees and near-term development milestone payments totaling up to $11 million MALVERN, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene
MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 9627149Webcast: Available on the events section of the
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financial results along with a general business update. "All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologic
MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 1773288Webcast: Available on the events section of the Ocuge
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2. All subjects from multiple dose levels in Phase 2 to date demonstrated a very favorable safety and tolerability profile.Positive 2-year long-term data across multiple mutations of retinitis pigmentosa (RP) from the Phase 1/2 clinical trial of OCU400 demonstrated a durable and statistically significant (p=0.005) improvement in visual f
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international calle
Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trialNew data on Phase 1/2 clinical trials for OCU410, OCU410ST and OCU400 to be presented at upcoming Clinical Showcase MALVERN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel
This live feed shows all institutional transactions in real time.
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G - Ocugen, Inc. (0001372299) (Subject)
Live Leadership Updates
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN) investors that a lawsuit was filed on behalf of investors that purchased Ocugen securities. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On April 1, 2024, Ocugen filed a Cur
MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO). "I'm very pleased to name Dr. Qamar as the CMO at Ocugen," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "This appointment recognizes her invaluable contributions to building a strong clinical team, overseeing a well-conducted Phase 1/2 gene therapy trial, and establishing relationships with leading medical and academic institutions and key o
MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Bob Smith, former Senior Vice President, Global Gene Therapy Business at Pfizer, has joined the Company's Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company's differentiated capabilities; and promoting access to the Company's the
Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth join the Board of Trustees at the largest national, independent donor-advised fund public charity National Philanthropic Trust (NPT), the largest national, independent public charity that manages donor-advised funds, and one of the leading grantmaking institutions in the U.S., is pleased to announce the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees. "As NPT continues to grow, innovate, and advance philanthropy around the world, we welcome these three accomplished professionals to our Board of Trustees," said Eileen Heisman, CEO of National Philanthropic Trust. "N
MALVERN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the appointment of Quan A. Vu to Chief Financial Officer & Chief Business Officer. "Quan has quickly become a tremendous asset for Ocugen and his comprehensive healthcare and financial expertise is providing valuable insight toward reaching our corporate goals," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "With Quan now overseeing both finance and business development, there will be a fully integr
MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company's pipeline. "Expanding Ocugen's product portfolio and capabilities, in line with our long-term strategy, is imperative for 2023," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "We are very excited to have Quan join our leadership tea
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer. Arun Upadhyay, PhD, previously Senior Vice President, Research & Development, will now serve as the Company's Chief Scientific Officer, overseeing the development and manufacturing of Ocugen's clinical and commercial product portfolio and evaluating new technologies. "We are extremely pleased to have Dr. Hopkins driving our clinical programs as his expertise acro